Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AMC NASDAQ:ASND NYSE:EPL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMCAMC Entertainment$2.95+1.7%$3.06$2.45▼$5.76$1.25B1.4311.23 million shs12.51 million shsASNDAscendis Pharma A/S$175.71+4.5%$168.04$111.09▼$183.00$10.28B0.38505,218 shs838,000 shsEPLEPL Oil & Gas$0.00$0.00▼$0.00N/AN/AN/AN/A7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMCAMC Entertainment+1.03%+2.43%-12.20%+0.85%-46.02%ASNDAscendis Pharma A/S+4.48%+1.51%+1.48%+22.59%+28.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMCAMC Entertainment3.1902 of 5 stars2.92.00.03.51.90.00.6ASNDAscendis Pharma A/S3.4863 of 5 stars4.53.00.00.02.01.70.6EPLEPL Oil & GasN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMCAMC Entertainment 1.75Reduce$4.2644.55% UpsideASNDAscendis Pharma A/S 3.00Buy$220.6725.59% UpsideEPLEPL Oil & Gas 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ELT, BOA, AMC, ASND, and EPL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025ASNDAscendis Pharma A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$250.006/13/2025ASNDAscendis Pharma A/SOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$215.00 ➝ $224.006/9/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$201.00 ➝ $216.006/3/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$196.00 ➝ $201.005/29/2025AMCAMC EntertainmentCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell ➝ Sell$2.30 ➝ $2.605/16/2025AMCAMC EntertainmentB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$3.005/15/2025AMCAMC EntertainmentB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold5/12/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.005/5/2025ASNDAscendis Pharma A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$180.00 ➝ $250.005/2/2025ASNDAscendis Pharma A/SRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$205.00 ➝ $210.005/2/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$200.00 ➝ $245.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMCAMC Entertainment$4.64B0.27N/AN/A($4.25) per share-0.69ASNDAscendis Pharma A/S$393.54M27.29N/AN/A($1.88) per share-93.46EPLEPL Oil & GasN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMCAMC Entertainment-$352.60M-$0.98N/AN/AN/A-8.60%N/A-5.68%8/1/2025 (Estimated)ASNDAscendis Pharma A/S-$409.12M-$6.28N/A732.13N/A-93.22%N/A-33.29%9/2/2025 (Estimated)EPLEPL Oil & GasN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest ELT, BOA, AMC, ASND, and EPL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/1/2025Q2 2025AMCAMC Entertainment-$0.07N/AN/AN/A$1.30 billionN/A5/7/2025Q1 2025AMCAMC Entertainment-$0.61-$0.58+$0.03-$0.47$983.23 million$862.50 million5/1/2025Q1 2025ASNDAscendis Pharma A/S-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMCAMC EntertainmentN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/AEPLEPL Oil & GasN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMCAMC EntertainmentN/A0.420.42ASNDAscendis Pharma A/SN/A1.040.71EPLEPL Oil & GasN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMCAMC Entertainment28.80%ASNDAscendis Pharma A/SN/AEPLEPL Oil & GasN/AInsider OwnershipCompanyInsider OwnershipAMCAMC Entertainment0.32%ASNDAscendis Pharma A/S40.00%EPLEPL Oil & GasN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMCAMC Entertainment33,382431.95 million430.57 millionOptionableASNDAscendis Pharma A/S1,01761.13 million36.68 millionOptionableEPLEPL Oil & GasN/AN/AN/ANot OptionableELT, BOA, AMC, ASND, and EPL HeadlinesRecent News About These CompaniesUK opposition leader calls for end to windfall taxJune 13, 2025 | upstreamonline.comUBadenoch: Scrap net zero windfall tax on oil companiesJune 13, 2025 | telegraph.co.ukNorth Sea Oil Producer Slams the UK's Windfall TaxMay 27, 2025 | oilprice.comONorth Sea oil and gas: Why the bridge to the future is being burned, as 600 Aberdeen job losses showMay 25, 2025 | scotsman.comSHibiscus Petroleum sees stronger cashflows, eyes growth despite UK levy impactMay 23, 2025 | thestar.com.myTThousands of Business Figures Call for Immediate End to UK EPLMay 22, 2025 | rigzone.comRWindfall tax 'destroying' North Sea oil and threatening growth, analysts warnMay 21, 2025 | msn.comPoll: 68% back UK oil and gas amid rising NE job lossesMay 10, 2025 | heraldscotland.comHEagle Plains Provides Update on Saskatchewan Gold and VMS ProjectsMay 8, 2025 | accessnewswire.comAMajor oil and gas firm to cut 250 jobs from Scottish workforceMay 7, 2025 | uk.news.yahoo.comOil and gas firm to cut 250 jobs from Scottish workforceMay 7, 2025 | news.stv.tvNThe UK North Sea’s biggest foe is indecisionApril 25, 2025 | ft.comWhy the UK can’t get a grip of its energy crisisApril 16, 2025 | msn.comNorth Sea oil deals allow companies to offset billions in tax liabilitiesApril 12, 2025 | ft.comJim Ratcliffe: Labour’s North Sea shutdown raises threat of UK blackoutsApril 2, 2025 | yahoo.comNorth Sea oil firm Serica cuts output guidance after Storm Éowyn delaysApril 2, 2025 | msn.comJudge denies Crum & Forster's US Fire Insurance Company's $13.5M collateral demand in bond caseApril 1, 2025 | insurancebusinessmag.comINorth Sea Taskforce Urges Windfall Tax Replacement Before 2030March 31, 2025 | oilprice.comOGetting its 'buzz' back: UK North Sea dealmaking on the riseMarch 29, 2025 | upstreamonline.comU'Another seven billion barrels of oil could be extracted from North Sea'March 25, 2025 | news.stv.tvNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off3 Industrial Leaders Boosting Dividends as the Sector OutperformsBy Leo Miller | June 24, 2025View 3 Industrial Leaders Boosting Dividends as the Sector Outperforms1999 Again? The Danger of These 3 Companies Making Bitcoin BetsBy Gabriel Osorio-Mazilli | July 8, 2025View 1999 Again? The Danger of These 3 Companies Making Bitcoin BetsTech, Financials, Industrials: 3 Leading Sectors of 2025By Ryan Hasson | June 23, 2025View Tech, Financials, Industrials: 3 Leading Sectors of 2025ELT, BOA, AMC, ASND, and EPL Company DescriptionsAMC Entertainment NYSE:AMC$2.95 +0.05 (+1.72%) Closing price 07/9/2025 03:56 PM EasternExtended Trading$2.96 +0.00 (+0.17%) As of 04:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AMC Entertainment Holdings, Inc., through its subsidiaries, engages in the theatrical exhibition business. It owns, operates, or has interests in theatres in the United States and Europe. The company was founded in 1920 and is headquartered in Leawood, Kansas.Ascendis Pharma A/S NASDAQ:ASND$175.71 +7.54 (+4.48%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$175.54 -0.18 (-0.10%) As of 07/9/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.EPL Oil & Gas NYSE:EPLEPL Oil & Gas, Inc., formerly Energy Partners, Ltd., is an independent oil and natural gas exploration and production company based in New Orleans, Louisiana and Houston, Texas. The Company's operations are concentrated in the United States, Gulf of Mexico shelf focusing on state and federal waters offshore Louisiana, which it considers its core area. On February 14, 2011, the Company acquired an asset package consisting of certain shallow-water Gulf of Mexico shelf oil and natural gas interests surrounding the Mississippi River delta and a related gathering system (the ASOP Properties) from Anglo-Suisse Offshore Partners, LLC (ASOP). In April 2013, it sold certain non-operated assets. In June 2014, Energy XXI (Bermuda) Limited completed the acquisition of EPL Oil & Gas Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
